Evidence map›Paper›PMID 28140789›Full record

ReviewRadiation research2017

p53 and RAD9, the DNA Damage Response, and Regulation of Transcription Networks.

Howard B Lieberman, Sunil K Panigrahi, Kevin M Hopkins, Li Wang, Constantinos G Broustas

Open access · bronzeAbstract readReview
In one paragraph

Review in Radiation research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Uterine fibroids show evidence of shared genetic architecture with blood pressure traits.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2025
    Article
  5. Research progress on the role of the NEIL family in cancer.Frontiers in cell and developmental biology · 2025
    Review
  6. Article
  7. Article
  8. Precision clinical medicine · 2024
    Article
  9. Loss of fragile WWOX gene leads to senescence escape and genome instability.Cellular and molecular life sciences : CMLS · 2023
    Article
  10. Review
  11. The Role of Protein Arginine Methyltransferases in DNA Damage Response.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Hypermethylation ofEXCLI journal · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Howard B Liebermana   Center for Radiological Research, Columbia University College of Physicians and Surgeons, New York, New York 10032; and.
Sunil K Panigrahia   Center for Radiological Research, Columbia University College of Physicians and Surgeons, New York, New York 10032; and.
Kevin M Hopkinsa   Center for Radiological Research, Columbia University College of Physicians and Surgeons, New York, New York 10032; and.
Li Wanga   Center for Radiological Research, Columbia University College of Physicians and Surgeons, New York, New York 10032; and.
Constantinos G Broustasa   Center for Radiological Research, Columbia University College of Physicians and Surgeons, New York, New York 10032; and.
Columbia University · US

Funding

Mechanisms of Radioresistance and Cell Cycle ProgressionR01CA130536 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LIEBERMAN, HOWARD B. · 2007 to 2016
$3.5M
NCI NIH HHS R01 CA130536
6 · The paper itself

Abstract

The way cells respond to DNA damage is important since inefficient repair or misrepair of lesions can have deleterious consequences, including mutation, genomic instability, neurodegenerative disorders, premature aging, cancer or death. Whether damage occurs spontaneously as a byproduct of normal metabolic processes, or after exposure to exogenous agents, cells muster a coordinated, complex DNA damage response (DDR) to mitigate potential harmful effects. A variety of activities are involved to promote cell survival, and include DNA repair, DNA damage tolerance, as well as transient cell cycle arrest to provide time for repair before entry into critical cell cycle phases, an event that could be lethal if traversal occurs while damage is present. When such damage is prolonged or not repairable, senescence, apoptosis or autophagy is induced. One major level of DDR regulation occurs via the orchestrated transcriptional control of select sets of genes encoding proteins that mediate the response. p53 is a transcription factor that transactivates specific DDR downstream genes through binding DNA consensus sequences usually in or near target gene promoter regions. The profile of p53-regulated genes activated at any given time varies, and is dependent upon type of DNA damage or stress experienced, exact composition of the consensus DNA binding sequence, presence of other DNA binding proteins, as well as cell context. RAD9 is another protein critical for the response of cells to DNA damage, and can also selectively regulate gene transcription. The limited studies addressing the role of RAD9 in transcription regulation indicate that the protein transactivates at least one of its target genes, p21/waf1/cip1, by binding to DNA sequences demonstrated to be a p53 response element. NEIL1 is also regulated by RAD9 through a similar DNA sequence, though not yet directly verified as a bonafide p53 response element. These findings suggest a novel pathway whereby p53 and RAD9 control the DDR through a shared mechanism involving an overlapping network of downstream target genes. Details and unresolved questions about how these proteins coordinate or compete to execute the DDR through transcriptional reprogramming, as well as biological implications, are discussed.

Indexed as

DNA DamageGene Regulatory NetworksTranscriptional ActivationCell Cycle ProteinsGenomic InstabilityHumansTranscription, GeneticTumor Suppressor Protein p53Cell Cycle Proteinsrad9 proteinTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID28140789
PMCPMC6061921
OpenAlexW2584071387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.